Cost-effectiveness analysis of TNF-α blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system

Dermatologic Therapy

Volumn 23, Issue SUPPL. 1, 2010, Pages

  Portu, Simona De ^a   Giglio, Micol Del ^b   Altomare, Gianfranco ^c   Arcangeli, Fabio ^d   Berardesca, Enzo ^e   Calzavara Pinton, Piergiacomo ^f   Lotti, Torello ^g   Martini, Patrizia ^h   Peserico, Andrea ⁱ   Simonacci, Marco ^j   Vena, Gino A ^k   Girolomoni, Giampiero ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Cesena Hospital   (Italy)

^e SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h Lucca Hospital   (Italy)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j Macerata Hospital   (Italy)

^k UNIVERSITY OF BARI   (Italy)

more..

Author keywords

Adalimumab; Biologics; Cost; Cost effectiveness; Etanercept; Infliximab; Psoriasis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; ITALY; OPEN STUDY; PATIENT ASSESSMENT; PSORIASIS VULGARIS; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HUMANS; IMMUNOGLOBULIN G; ITALY; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 74949140245     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2009.01280.x     Document Type: Article

References (38)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007 : 370 : 263 271.
2. Gladman DD. Psoriatic arthritis. Dermatol Ther 2009 : 22 : 40 55.
3. Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009 : 35 : 313 324.
4. Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. Dermatology 2006 : 212 : 123 127.
5. Saraceno R, Griffiths CE. A European perspective on the challenges of managing psoriasis. J Am Acad Dermatol 2006 : 54 : S81 S84.
6. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005 : 152 : 597 615.
7. Colombo GL, Altomare GF, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008 : 4 : 559 568.
8. Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004 : 151 : 3 17.
9. Reich K, Yasothan U, Kirkpatrick P. Ustekinumab. Nat Rev Drug Discov 2009 : 8 : 355 356.
10. Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets 2008 : 12 : 1085 1096.
11. Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther 2009 : 22 : 56 60.
12. Radtke MA, Augustin M. Economic considerations in psoriasis management. Clin Dermatol 2008 : 26 : 424 431.
13. Steele T, Pawaskar M, Balkrishnan R, Fleischer A, Feldman SR. Does cost-effectiveness play a role in clinical trials? Dermatol Ther 2007 : 20 : 110 119.
14. Sizto S, Bansback N, Feldman SR, William MK, Anis AH. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2009 : 160 : 1264 1272.
15. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 : 366 : 1367 1374.
16. Leonardi CL, Powers JL, Matherson RT, et al. Etanercept as a monotherapy in patients with psoriasis. N Engl J Med 2003 : 349 : 2014 2022.
17. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 2007 : 143 : 719 726.
18. van de Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008 : 159 : 1177 1185.
19. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005 : 152 : 1304 1312.
20. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006 : 55 : 598 606.
21. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 : 366 : 1367 1374.
22. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 : 56 : 31 44.
23. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007 : 56 : 476 488.
24. Gordon KB, Gottlieb AB, Leonardi CL, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006 : 17 : 9 17.
25. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007 : 156 : 945 950.
26. NICE technology appraisal guidance 104. Etanercept and infliximab for the treatment of adults with psoriatic arthritis. 2007. http://www.nice.org.uk/ TA104. Accessed July 1, 2009.
27. Ministry of Health Degree 22nd July 1996. Prestazioni di Assistenza specialistica ambulatoriale erogabili nell'ambito del Servizio Sanitario Nazionale e relative tariffe. Suppl. to Gazzetta Ufficiale n. 216, September 14, 1996.
28. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumor necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008 : 22 : 341 344.
29. Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008 : 57 : 290 295.
30. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994 : 3 : 95 104.
31. Garattini L, Grilli R, Scopelliti D, Mantovani L. A proposal for Italian Guidelines in pharmacoeconomics. Pharmacoeconomics 1995 : 7 : 1 6.
32. Capri S, Ceci A, Terranova L, et al. Guidelines for economic evaluation in Italy: recommendation from the Italian group of pharmacoeconomic studies. Drug Inform J 2001 : 35 : 189 201.
33. Nelson AA, Pearce DJ, Fleischer AB Jr., Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis on subjective and odjective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol 2008 : 58 : 125 135.
34. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 : 158 : 558 566.
35. Moore A, Gordon KB, Kang S, Gottlieb A, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007 : 56 : 598 603.
36. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008 : 58 : 443 446.
37. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006 : 213 : 102 110.
38. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstädter F, Landthaler M, Stolz W. Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications. Br J Dermatol 2001 : 144 : 1154 1160.